Stryker (SYK) has announced an agreement to acquire Inari Medical, Inc. (NARI) in a cash transaction valued at $4.9 billion, with an offer of $80 per share. This strategic purchase will enhance Stryker's presence in the burgeoning field of venous thromboembolism (VTE) by incorporating Inari's advanced peripheral vascular capabilities.
Kevin Lobo, the Chairman and CEO of Stryker, stated, "This acquisition broadens Stryker's ability to deliver critical interventions for patients suffering from peripheral vascular diseases. Inari's innovations are set to elevate care standards for VTE patients, strengthening Stryker's influence in endovascular treatments."
To execute the deal, Stryker will initiate a tender offer to acquire all outstanding shares of Inari's common stock at $80 apiece. The boards of directors for both companies have given unanimous approval to the transaction.
The acquisition is expected to finalize by the end of the first quarter of 2025, pending standard regulatory approvals and customary closing conditions.
